Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice

INTRODUCTION: In clinical trials, toxicity leading to discontinuation of tenofovir (TDF) is a rare occurrence (3% by two years)[1, 2]; however, in clinical practice it seems to be higher. Previous studies suggested that TDF toxicity is higher when it is co-administered with ritonavir-boosted proteas...

Descripción completa

Detalles Bibliográficos
Autores principales: Costarelli, Silvia, Cozzi-Lepri, Alessandro, Lapadula, Giuseppe, Bonora, Stefano, Madeddu, Giordano, Maggiolo, Franco, Antinori, Andrea, Gori, Andrea, D'Arminio-Monforte, Antonella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P039
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224916/
https://www.ncbi.nlm.nih.gov/pubmed/25394078
http://dx.doi.org/10.7448/IAS.17.4.19571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224916/
https://www.ncbi.nlm.nih.gov/pubmed/25394078
http://dx.doi.org/10.7448/IAS.17.4.19571

Ejemplares similares